Present and Future Research on Anal Squamous Cell Carcinoma

Area of Science:

• Oncology
• Cancer Research

Background:

• Anal squamous cell carcinoma (aSCC) is a rare cancer with limited treatment advancements over the past three decades.
• The majority of aSCC cases are associated with HPV genotype 16.

Purpose of the Study:

• To summarize recent progress and future directions in the treatment and understanding of anal squamous cell carcinoma.
• To highlight the impact of novel therapeutic strategies and biomarkers in managing this orphan disease.

Main Methods:

• Review of ongoing clinical trials investigating combination therapies for localized and advanced aSCC.
• Discussion of the role of emerging biomarkers, such as HPV circulating tumor DNA (ctDNA), in prognostic assessment and treatment guidance.

Main Results:

• Significant momentum in aSCC research driven by taxane-based chemotherapy and immunotherapy.
• Approximately 20 clinical trials are evaluating anti-PD1/L1 combinations with radiotherapy, chemotherapy, vaccines, and other targeted agents.
• HPV ctDNA liquid biopsy shows high sensitivity and specificity for improved prognostic measurement and treatment strategy guidance.

Conclusions:

• The landscape of anal squamous cell carcinoma treatment is rapidly evolving with new therapeutic options.
• Emerging biomarkers like HPV ctDNA are crucial for personalized medicine approaches in aSCC.
• Continued research into potential molecular targets is essential for future clinical advancements in HPV-related aSCC.